Oisin Biotechnologies vs Deciduous Therapeutics

Seattle biotech using a non-viral lipid delivery platform to deliver gene-directed payloads that destroy senescent cells.

San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.

For subscribers

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →